Arbutus Biopharma Corp (ABUS) stock
ABUSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 12/3082% below fair value
$3.88+0.06 (+1.57%)
Close on Nov 11, 2026Market cap $767.65MP/E 3.5Yield –
Arbutus Biopharma profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Arbutus Biopharma's profit margin for the twelve months ending Sep 30, 2026 was 121.2%. For fiscal 2025 it was -237.9%, against -1133.0% the year before. The highest annual figure on record is 209.9% in fiscal 2012.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -237.9% | +895.2 |
| FY2024 | Dec 31, 2024 | -1133.0% | −731.5 |
| FY2023 | Dec 31, 2023 | -401.6% | −223.6 |
| FY2022 | Dec 31, 2022 | -178.0% | +515.9 |
| FY2021 | Dec 31, 2021 | -693.9% | +228.1 |
| FY2020 | Dec 31, 2020 | -922.0% | +1635.4 |
| FY2019 | Dec 31, 2019 | -2557.4% | −1597.6 |
| FY2018 | Dec 31, 2018 | -959.8% | −170.9 |
| FY2017 | Dec 31, 2017 | -788.9% | +24976.6 |
| FY2016 | Dec 31, 2016 | -25765.5% | −25496.1 |
| FY2015 | Dec 31, 2015 | -269.5% | −9.7 |
| FY2014 | Dec 31, 2014 | -259.7% | −168.8 |
| FY2013 | Dec 31, 2013 | -90.9% | −300.9 |
| FY2012 | Dec 31, 2012 | 209.9% | +269.9 |
| FY2011 | Dec 31, 2011 | -60.0% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | 19770.9% | +21234.4 |
| Q2 FY2026 | Jun 30, 2026 | -507.2% | −530.7 |
| Q1 FY2026 | Mar 31, 2026 | 94.7% | +1485.1 |
| Q4 FY2025 | Dec 31, 2025 | -357.4% | +438.8 |
| Q3 FY2025 | Sep 30, 2025 | -1463.5% | +9.0 |
| Q2 FY2025 | Jun 30, 2025 | 23.5% | +1170.4 |
| Q1 FY2025 | Mar 31, 2025 | -1390.4% | −223.6 |
| Q4 FY2024 | Dec 31, 2024 | -796.2% | +104.1 |
| Q3 FY2024 | Sep 30, 2024 | -1472.5% | −1040.9 |
| Q2 FY2024 | Jun 30, 2024 | -1146.9% | −779.4 |
| Q1 FY2024 | Mar 31, 2024 | -1166.8% | −922.4 |
| Q4 FY2023 | Dec 31, 2023 | -900.3% | −549.1 |
| Q3 FY2023 | Sep 30, 2023 | -431.6% | −136.5 |
| Q2 FY2023 | Jun 30, 2023 | -367.5% | −267.9 |
| Q1 FY2023 | Mar 31, 2023 | -244.3% | −119.0 |
| Q4 FY2022 | Dec 31, 2022 | -351.2% | +313.8 |
| Q3 FY2022 | Sep 30, 2022 | -295.1% | +278.4 |
| Q2 FY2022 | Jun 30, 2022 | -99.7% | +732.8 |
| Q1 FY2022 | Mar 31, 2022 | -125.3% | +649.9 |
| Q4 FY2021 | Dec 31, 2021 | -665.0% | +49.2 |
| Q3 FY2021 | Sep 30, 2021 | -573.6% | +657.9 |
| Q2 FY2021 | Jun 30, 2021 | -832.4% | +98.0 |
| Q1 FY2021 | Mar 31, 2021 | -775.2% | +154.4 |
| Q4 FY2020 | Dec 31, 2020 | -714.2% | +809.5 |
| Q3 FY2020 | Sep 30, 2020 | -1231.5% | +1463.8 |
| Q2 FY2020 | Jun 30, 2020 | -930.4% | +2640.0 |
| Q1 FY2020 | Mar 31, 2020 | -929.6% | +2494.7 |
| Q4 FY2019 | Dec 31, 2019 | -1523.7% | −436.2 |
| Q3 FY2019 | Sep 30, 2019 | -2695.3% | −1153.2 |
| Q2 FY2019 | Jun 30, 2019 | -3570.4% | −3818.9 |
| Q1 FY2019 | Mar 31, 2019 | -3424.3% | −2210.6 |
| Q4 FY2018 | Dec 31, 2018 | -1087.5% | +330.4 |
| Q3 FY2018 | Sep 30, 2018 | -1542.1% | −1373.8 |
| Q2 FY2018 | Jun 30, 2018 | 248.5% | +2005.5 |
| Q1 FY2018 | Mar 31, 2018 | -1213.7% | +6712.7 |
| Q4 FY2017 | Dec 31, 2017 | -1418.0% | – |
| Q3 FY2017 | Sep 30, 2017 | -168.3% | – |
| Q2 FY2017 | Jun 30, 2017 | -1757.0% | – |
| Q1 FY2017 | Mar 31, 2017 | -7926.4% | – |
See a number that looks wrong?